Hansa Biopharma Reports Second Quarter and First Half Year 2026 Financial Results
Hansa Biopharma AB announced its financial results for the second quarter and first half of 2026. The company detailed a €115 million out-licensing agreement and positive outcomes from a European confirmatory trial.
Hansa Biopharma AB released its financial results for the second quarter and the first half of 2026, covering the period up to June 22, 2026. A key development for the first half of the year was an out-licensing agreement generating €115 million in revenue.
The company also reported positive data from its European confirmatory trial, known as PAES. This data is expected to support an application for full European approval of the company's therapeutic. Additionally, the strength and clinical relevance of Hansa Biopharma's ConfIdeS Phase 3 trial data have been further recognized.
CEO Renée Aguiar-Lucander characterized the quarter as a defining period for the company. "This was a defining quarter for Hansa," she stated, highlighting the out-licensing deal, the PAES results, and the ConfIdeS data as significant achievements.
Hansa Biopharma continues to advance its commercialization efforts and anticipates decisions on key market regulatory processes in the latter half of the year. The company reiterated its strategic priorities for the upcoming period alongside the financial results announcement.